Brief: AB Science: Results From masitinib Study In Pancreatic Cancer

AB Science SA

10/06/2021 17:59

June 10 (Reuters) - AB Science SA  ABS.PA :
    * RESULTS FROM MASITINIB STUDY AB12005 IN PANCREATIC CANCER
    * NO SURVIVAL BENEFIT WAS SEEN FOR OVERALL STUDY POPULATION,
WHICH
INCLUDED METASTATIC PATIENTS
    * MASITINIB PLUS GEMCITABINE CONFERS MEANINGFUL OVERALL
SURVIVAL
BENEFIT OF +1.8 MONTHS RELATIVE TO CONTROL IN LAPC PATIENTS WITH
PAIN, AND SIGNIFICANT 54% REDUCED RISK OF DEATH (P=0.005)
    * MASITINIB PLUS GEMCITABINE INCREASED MEDIAN PROGRESSION
FREE
SURVIVAL BY 3.6 MONTHS, CORRESPONDING TO A SIGNIFICANT 54%
REDUCED RISK OF DISEASE PROGRESSION (P=0.004) IN LAPC PATIENTS
WITH PAIN

Source text for Eikon:  ID:nGNE9ZNCVM 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))